Although associated with certain central nervous system-related adverse effects, Lorlatinib is generally well tolerated and significantly expands therapeutic options for patients with ALK-positive NSCLC, representing a frontier in current ALK-targeted therapy. Here, ALK is linked to non-small cell lung carcinoma.